Zacks Reaffirms Neutral Rating on AthenaHealth (ATHN)
A number of other firms have also recently commented on ATHN. Analysts at Lazard Capital initiated coverage on shares of AthenaHealth in a research note to investors on Wednesday, May 23rd. They set a “buy” rating on the stock. Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of AthenaHealth from an “underweight” rating to an “equal weight” rating in a research note to investors on Thursday, May 3rd. Finally, analysts at Auriga reiterated a “sell” rating on shares of AthenaHealth in a research note to investors on Monday, April 30th.
Shares of AthenaHealth opened at 75.91 on Tuesday. AthenaHealth has a one year low of $38.97 and a one year high of $78.24. The company has a market cap of $2.721 billion and a P/E ratio of 149.43.
AthenaHealth last issued its quarterly earnings data on Thursday, April 26th. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The company’s revenue for the quarter was up 38.1% on a year-over-year basis. On average, analysts predict that AthenaHealth will post $0.27 earnings per share next quarter.
athenahealth, Inc. (athenahealth) is a business services company that provides ongoing billing, clinical-related, and other related services to its customers.